YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
iBio, Inc. SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the a…
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment…
(RTTNews) - iBio, Inc. (IBIO) announced new preclinical results showing that a single dose of its antibody candidate IBIO-610 reduced active Activin E levels by up to 98% in obese non-human primates, with suppression lasting through eight…
Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while…
With 16 hedge funds having stakes in the stock, iBio, Inc. (NASDAQ:IBIO) is among the 10 Under-the-Radar AI Stocks to Buy in 2026. On June 8, Raymond James initiated coverage of iBio, Inc. (NASDAQ:IBIO) with an Outperform rating and a $5 p…
SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth Stoner, M.D., M.S. to…
* iBio press release [https://seekingalpha.com/pr/20394853-ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update] (IBIO [https://seekingalpha.com/symbol/IBIO]): Q2 GAAP EPS of -$0.09. * iBio held cash, cash equiv…
CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company'…
Wall Street expects a year-over-year increase in earnings on lower revenues when iBio, Inc. (IBIO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earning…
iBio (IBIO [https://seekingalpha.com/symbol/IBIO]) on Friday announced [https://seekingalpha.com/pr/20359098-ibio-announces-26-million-private-placement] a securities purchase agreement with existing institutional investors for a private p…
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-…
(RTTNews) - Biotechnology stocks saw notable movement in after-hours trading on Monday, with several companies posting strong gains. Below is a structured look at the key movers and the developments driving their performance. Exicure, Inc.…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 852,838,067 0.0658 0.0476 0.05 +0.0134 Conf…
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place Decembe…
* iBio press release [https://seekingalpha.com/pr/20304986-ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update] (IBIO [https://seekingalpha.com/symbol/IBIO]): Q1 GAAP EPS of -$0.11. * Revenue of $0.1M beats by…
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human primate data for our pote…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an o…
Arquitos Capital Management, an investment management firm, released its second-quarter 2025 investor letter. During the period, the fund delivered a net return of 13.1%, bringing year-to-date gains to an impressive 28.8% as of June 30, 20…
* iBio press release [https://seekingalpha.com/pr/20222653-ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update] (NASDAQ:IBIO [https://seekingalpha.com/symbol/IBIO]): FY GAAP EPS of -$1.75. * Revenue of $0.4M (+73.…
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update…
(RTTNews) - iBio, Inc. (IBIO), an AI-driven developer of precision antibody therapies, has priced an underwritten public offering of pre-funded warrants for 71.54 million shares and accompanying Series G and Series H warrants, raising appr…
* iBio (NASDAQ:IBIO [https://seekingalpha.com/symbol/IBIO]) announced a $50M underwritten public offering. * The offering includes 71.54M pre-funded warrants and Series G and H warrants to purchase a total of 71.54M shares. * Each unit (1…
SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “offering”) of (i) pre-funded warrants to p…
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today. [postmarket] AFTER HOURS GAINERS TICKER CHANGE COMMENT LASE [https://www.chartmill.com/stock/quote/LASE/prof…
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “offering”) of (i) pre-funded warrants to…
* Impact Biomedical (NYSE:IBO [https://seekingalpha.com/symbol/IBO]) announced on Monday that the US Patent and Trademark Office has issued a patent titled “Composition and Method of Controlling Infectious Diseases with Functional Fragranc…
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists…
Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an A…
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to b…
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement with institutional i…
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting A…
Enable social media cookies to share Which stocks are moving on Monday? By Mill Chart Last update: Apr 7, 2025 Here are the top movers in Monday's session, showcasing the stocks with significant price changes. Today's top gainers TickerCha…
Enable social media cookies to share Keep an eye on the top gainers and losers in Monday's session. By Mill Chart Last update: Apr 7, 2025 Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top ga…
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E ant…
We recently published a list of 20 Stocks Insiders Were Buying In Q1 2025. In this article, we are going to take a look at where iBio, Inc. Common Stock (NASDAQ:IBIO) stands against other stocks insiders were buying in Q1 2025. About 30 mi…